Company Filing History:
3 out of 154 
3 out of 5,081 
3 out of 1,743 
Years Active: 2010-2012
Title: Philipe Maillard: Innovator in Cancer Therapy
Introduction
Philipe Maillard is a notable inventor based in Saint-Cyr-l'Ecole, France. He has made significant contributions to the field of cancer therapy and diagnosis, holding three patents that reflect his innovative work. His research focuses on the development of new compounds that can enhance cancer treatment and diagnostic methods.
Latest Patents
Philipe Maillard's latest patents include groundbreaking inventions related to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs. These compounds are designed for use in over-expressing GB3 receptor cells. The formula for these compounds is represented as STxB-Z(n)-Cys-Y(m)-T. This innovative approach aims to improve tumor diagnosis and drug delivery specifically targeting GB3 expressing tumors.
Career Highlights
Throughout his career, Philipe Maillard has worked with prestigious institutions such as Institut Curie and the Centre National de La Recherche Scientifique. His work in these organizations has allowed him to advance his research and contribute to significant developments in cancer therapy.
Collaborations
Philipe has collaborated with esteemed colleagues, including Ludger Johannes and David Grierson. These partnerships have fostered a collaborative environment that enhances the potential for innovative breakthroughs in cancer research.
Conclusion
Philipe Maillard is a distinguished inventor whose work in cancer therapy and diagnosis is paving the way for new treatment options. His innovative patents and collaborations highlight his commitment to advancing medical science.